Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
(NASDAQ:BMEA), SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase 7,500 shares of the Company's […]